{"id":"https://openalex.org/W2004305668","doi":"https://doi.org/10.1038/sj.clpt.6100242","title":"Pharmacokinetics and Pharmacodynamics of the Novel Daily Rivastigmine Transdermal Patch Compared With Twice-daily Capsules in Alzheimer's Disease Patients","display_name":"Pharmacokinetics and Pharmacodynamics of the Novel Daily Rivastigmine Transdermal Patch Compared With Twice-daily Capsules in Alzheimer's Disease Patients","publication_year":2007,"publication_date":"2007-05-23","ids":{"openalex":"https://openalex.org/W2004305668","doi":"https://doi.org/10.1038/sj.clpt.6100242","mag":"2004305668","pmid":"https://pubmed.ncbi.nlm.nih.gov/17522596"},"language":"en","primary_location":{"id":"doi:10.1038/sj.clpt.6100242","doi":"https://doi.org/10.1038/sj.clpt.6100242","is_oa":false,"landing_page_url":"https://doi.org/10.1038/sj.clpt.6100242","pdf_url":null,"source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology & Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5052497721","display_name":"Gilbert Y. Lef\u00e8vre","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":true,"raw_author_name":"G Lef\u00e8vre","raw_affiliation_strings":["Novartis Pharma AG, Basel, Switzerland. gilbert.lefevre@novartis.com","Novartis Pharma AG, Basel, SWITZERLAND"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharma AG, Basel, Switzerland. gilbert.lefevre@novartis.com","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"Novartis Pharma AG, Basel, SWITZERLAND","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111626346","display_name":"Greg Sedek","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"G S\u0119dek","raw_affiliation_strings":["Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA","institution_ids":["https://openalex.org/I4210117619"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035840807","display_name":"S. S. Jhee","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S S Jhee","raw_affiliation_strings":["California Clinical Trials Medical Group, Glendale, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"California Clinical Trials Medical Group, Glendale, California, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072651394","display_name":"Mark T. Leibowitz","orcid":"https://orcid.org/0009-0007-0134-9836","observed_orcids":["https://orcid.org/0009-0007-0134-9836"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M T Leibowitz","raw_affiliation_strings":["California Clinical Trials Medical Group, Glendale, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"California Clinical Trials Medical Group, Glendale, California, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102094632","display_name":"H-La Huang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"H-La Huang","raw_affiliation_strings":["Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA","institution_ids":["https://openalex.org/I4210117619"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028183901","display_name":"Albert Enz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"A Enz","raw_affiliation_strings":["Novartis Pharma AG, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharma AG, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018835159","display_name":"Steve Maton","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S Maton","raw_affiliation_strings":["Novartis PharmOps, Horsham, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis PharmOps, Horsham, UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009531510","display_name":"Larry Ereshefsky","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L Ereshefsky","raw_affiliation_strings":["California Clinical Trials Medical Group, Glendale, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"California Clinical Trials Medical Group, Glendale, California, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029934646","display_name":"Francoise Pommier","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210092929","display_name":"Novartis (France)","ror":"https://ror.org/00geypp27","country_code":"FR","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210092929"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"F Pommier","raw_affiliation_strings":["Novartis Pharma SAS, Rueil-Malmaison, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharma SAS, Rueil-Malmaison, France","institution_ids":["https://openalex.org/I4210092929"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073799553","display_name":"Heinz Schmidli","orcid":"https://orcid.org/0000-0003-0934-1066","observed_orcids":["https://orcid.org/0000-0003-0934-1066"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"H Schmidli","raw_affiliation_strings":["Novartis Pharma AG, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharma AG, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5089523988","display_name":"Silke Appel\u2010Dingemanse","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"S Appel-Dingemanse","raw_affiliation_strings":["Novartis Pharma AG, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharma AG, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5052497721"],"corresponding_institution_ids":["https://openalex.org/I1283582996"],"apc_list":{"value":4410,"currency":"USD","value_usd":4410},"apc_paid":null,"fwci":6.9641,"has_fulltext":false,"cited_by_count":130,"citation_normalized_percentile":{"value":0.97070382,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":92,"max":99},"biblio":{"volume":"83","issue":"1","first_page":"106","last_page":"114"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12023","display_name":"Cholinesterase and Neurodegenerative Diseases","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12023","display_name":"Cholinesterase and Neurodegenerative Diseases","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10704","display_name":"Advancements in Transdermal Drug Delivery","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rivastigmine","display_name":"rivastigmine","score":0.9990000128746033},{"id":"https://openalex.org/keywords/transdermal-patch","display_name":"transdermal patch","score":0.984000027179718},{"id":"https://openalex.org/keywords/alzheimer-s-disease","display_name":"Alzheimer's disease","score":0.7879999876022339},{"id":"https://openalex.org/keywords/cholinesterase-inhibitors","display_name":"cholinesterase inhibitors","score":0.8870000243186951},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9660000205039978},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9990000128746033},{"id":"https://openalex.org/keywords/butyrylcholinesterase-inhibition","display_name":"butyrylcholinesterase inhibition","score":0.9390000104904175},{"id":"https://openalex.org/keywords/drug-exposure","display_name":"drug exposure","score":0.5989999771118164},{"id":"https://openalex.org/keywords/plasma-concentration-fluctuation","display_name":"plasma concentration fluctuation","score":0.5740000009536743}],"concepts":[{"id":"https://openalex.org/C2776332859","wikidata":"https://www.wikidata.org/wiki/Q411887","display_name":"Rivastigmine","level":5,"score":0.9405698776245117},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.8172606229782104},{"id":"https://openalex.org/C2775842315","wikidata":"https://www.wikidata.org/wiki/Q1145270","display_name":"Transdermal patch","level":3,"score":0.7899974584579468},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.7507760524749756},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.6896275877952576},{"id":"https://openalex.org/C2778778583","wikidata":"https://www.wikidata.org/wiki/Q147768","display_name":"Capsule","level":2,"score":0.6090846061706543},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.604522705078125},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5964503288269043},{"id":"https://openalex.org/C31896038","wikidata":"https://www.wikidata.org/wiki/Q415635","display_name":"Cholinesterase","level":2,"score":0.531816840171814},{"id":"https://openalex.org/C205679159","wikidata":"https://www.wikidata.org/wiki/Q3375179","display_name":"Transdermal","level":2,"score":0.4291940927505493},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.3732788562774658},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2629649043083191},{"id":"https://openalex.org/C2780904820","wikidata":"https://www.wikidata.org/wiki/Q415081","display_name":"Donepezil","level":4,"score":0.16969525814056396},{"id":"https://openalex.org/C2779483572","wikidata":"https://www.wikidata.org/wiki/Q83030","display_name":"Dementia","level":3,"score":0.06981199979782104},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.055002450942993164},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C59822182","wikidata":"https://www.wikidata.org/wiki/Q441","display_name":"Botany","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000068836","descriptor_name":"Rivastigmine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000279","descriptor_name":"Administration, Cutaneous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000544","descriptor_name":"Alzheimer Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D000544","descriptor_name":"Alzheimer Disease","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":false},{"descriptor_ui":"D001596","descriptor_name":"Benzylamines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D002091","descriptor_name":"Butyrylcholinesterase","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D002214","descriptor_name":"Capsules","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002800","descriptor_name":"Cholinesterase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D002800","descriptor_name":"Cholinesterase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D002800","descriptor_name":"Cholinesterase Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008954","descriptor_name":"Models, Biological","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010627","descriptor_name":"Phenethylamines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010636","descriptor_name":"Phenols","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D048448","descriptor_name":"Phenylcarbamates","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D048448","descriptor_name":"Phenylcarbamates","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D048448","descriptor_name":"Phenylcarbamates","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1038/sj.clpt.6100242","doi":"https://doi.org/10.1038/sj.clpt.6100242","is_oa":false,"landing_page_url":"https://doi.org/10.1038/sj.clpt.6100242","pdf_url":null,"source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology & Therapeutics","raw_type":"journal-article"},{"id":"pmid:17522596","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17522596","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacology and therapeutics","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9922999739646912,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307778","display_name":"Novartis","ror":"https://ror.org/02f9zrr09"},{"id":"https://openalex.org/F4320332736","display_name":"Novartis Pharma","ror":"https://ror.org/0013shd50"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":15,"referenced_works":["https://openalex.org/W170237590","https://openalex.org/W1971048984","https://openalex.org/W1992414019","https://openalex.org/W1996787470","https://openalex.org/W2016149437","https://openalex.org/W2024623973","https://openalex.org/W2031396820","https://openalex.org/W2050009016","https://openalex.org/W2052011640","https://openalex.org/W2065021421","https://openalex.org/W2067207334","https://openalex.org/W2105005652","https://openalex.org/W2142051176","https://openalex.org/W2414565701","https://openalex.org/W3216169949"],"related_works":["https://openalex.org/W2034596923","https://openalex.org/W2045413014","https://openalex.org/W2160552877","https://openalex.org/W2012483918","https://openalex.org/W1968338902","https://openalex.org/W1993825148","https://openalex.org/W2050009016","https://openalex.org/W4282835323","https://openalex.org/W1751954123","https://openalex.org/W2052011640"],"abstract_inverted_index":{"A":[0],"transdermal":[1],"patch":[2,27,53,64,132,149],"has":[3],"been":[4],"developed":[5],"for":[6],"the":[7,14,100,146,153],"cholinesterase":[8],"inhibitor":[9],"rivastigmine.":[10],"This":[11,31],"study":[12,36],"investigated":[13],"pharmacokinetics":[15],"and":[16,20,22,28,84,112],"pharmacodynamics":[17],"of":[18],"rivastigmine":[19],"NAP226-90,":[21],"compared":[23,98],"drug":[24],"exposure":[25,144],"between":[26,110],"capsule":[29,45,104,141,155],"administrations.":[30],"was":[32,150],"an":[33],"open-label,":[34],"parallel-group":[35],"in":[37,56],"Alzheimer's":[38],"disease":[39],"patients":[40],"randomized":[41],"to":[42,152],"receive":[43],"either":[44],"(1.5-6":[46],"mg":[47,102,124,158],"Q12H,":[48,159],"i.e.,":[49,160],"3-12":[50],"mg/day)":[51],"or":[52],"(5-20":[54],"cm2)":[55],"ascending":[57],"doses":[58],"through":[59],"four":[60],"14-day":[61],"periods.":[62],"The":[63],"showed":[65],"lower":[66,70],"Cmax":[67],"(ca.":[68,87],"30%":[69],"at":[71,89,117,122],"20":[72,90,118],"cm2,":[73,91],"19.5":[74],"versus":[75,81,93,120],"29.3":[76],"ng/ml),":[77],"longer":[78],"tmax":[79],"(8.0":[80],"1.0":[82],"h),":[83],"greater":[85],"AUC":[86],"1.8-fold":[88],"345":[92],"191":[94],"ng":[95],"x":[96],"h/ml)":[97],"with":[99,106,145],"6":[101],"Q12H":[103],"dose,":[105],"markedly":[107],"less":[108],"fluctuation":[109],"peak":[111],"trough":[113],"plasma":[114],"levels":[115],"(80%":[116],"cm2":[119,148],"620%":[121],"1.5":[123],"Q12H).":[125],"Plasma":[126],"butyrylcholinesterase":[127],"inhibition":[128],"rose":[129],"slowly":[130],"after":[131,140],"administration,":[133],"whereas":[134],"two":[135],"distinct":[136],"peaks":[137],"were":[138],"seen":[139],"administration.":[142],"Average":[143],"10":[147],"comparable":[151],"highest":[154],"dose":[156],"(6":[157],"12":[161],"mg/day).":[162]},"counts_by_year":[{"year":2026,"cited_by_count":6},{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":6},{"year":2019,"cited_by_count":9},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":9},{"year":2016,"cited_by_count":8},{"year":2015,"cited_by_count":6},{"year":2014,"cited_by_count":8},{"year":2013,"cited_by_count":5},{"year":2012,"cited_by_count":11}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}